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Introduction
Oral lesions form significant early clinical features of HIV infection [1] .
These lesions are often indicators of immune suppression and can be used for early testing, diagnosis and management of patients with HIV/ AIDS. Oral lesions therefore contribute largely to patients' morbidity, affecting the psychological and economic functioning of the individual and community [2] . They may be classified into infections such as fungal, viral and bacterial infections, neoplasms such as Kaposi's sarcoma and non-specific presentations such as aphthous ulcerations and salivary gland diseases [3, 4] . The overall prevalence of oral lesions in HIV infected patients has changed since the advent of combination Anti-Retroviral Therapy (cART). For instance, several studies have shown considerable reduction in prevalence of herpes labialis and periodontal diseases along with other oral lesions from 80% to about 30% after the institution of cART [5] and in HIVassociated opportunistic infections [6, 7] . Oral candidiasis (OC) has been shown to be the most common oral lesion seen in HIV infected patients, however with the advent of cART, most studies reported a decline in its occurrence. In a study of 93 patients, 7% of patients on protease inhibitors (PI) had oral candidiasis, compared with 36% in non-PI treated patients [8] . Schmidt-Westhausen et al. (2000) detected OC in 10 out of 103 (9.7%) of their study subjects who had been on cART for 4 weeks and in none after 6 months of therapy (N=61) [9] . Unlike most other oral manifestations of HIV, which decrease with use of cART, studies from the USA and the United Kingdom (UK) have described an increase in the prevalence of oral warts with cART [10] [11] [12] , which may reach statistical significance.
Other lesions that are showing a trend of rising prevalence include HIV-related salivary gland disease [10] . The goal of cART should be maximal and durable viral suppression, restoration and preservation of the immune system with resultant resolution of opportunistic illnesses and improvement in the quality of life through ease of use of the regimen with minimal side-effects to enhance adherence. This should translate to a reduction of HIV-related morbidity including oral manifestations. Reduction of viral load will prevent progressive immunodeficiency, decrease the risk of the emergence of resistant viruses and decrease the risk of viral transmission [13] . The potent combination therapies have proven effective in suppressing plasma-HIV viral load below detectable limits and elevating CD4+ lymphocyte cell counts. Consequently, the immune status for the therapy adherent patients improves significantly. However, some patients fail to achieve complete viral suppression [14, 15] . It has been shown in various studies that the prevalence of HIV-related oral lesions reduces significantly with cART. The reported percentage decrease varied from 10% in a USA study on 570 patients [10] to 50% in a Mexican study on selected 1000 HIV patients over a period of 12 years [16] .
In a Nigerian study about 80% of the lesions cleared with use of cART [7] . However, cART sometimes achieves suboptimal results with less than fifty percent of patients achieving therapeutic goal. This is due to a variety of reasons such as medication intolerance/ side effects, prior ineffective antiretroviral therapy and infection with a drugresistant strain of HIV. However, non-adherence with antiretroviral therapy is the major reason most individuals fail to benefit from cART [17] . Nearly all the reported studies had been conducted in industrialised countries and literatures concerning the behaviour of HIV related oral lesions in patients undergoing cART is scarce. This study therefore seeks to determine the prevalence of HIV related oral lesion on patients undergoing cART therapy and to assess the therapeutic effects of cART on the clinical presentations of these lesions and its relation to CD4+ cell count in a Nigerian adult population. Fisher's exact test was used for 2 × 2 tables or where the requirements for test could not be met. Paired T test applied to compare mean CD4 cell count at initiation of cART and on examination at recruitment. The 5% significance level was used.
Methods

Results
A total of 491 people living with HIV on cART were enrolled into the acknowledged the use of other medications along with cART to treat the lesions. The median duration of oral lesions was 9 ±(1-36) months and recurrence was reported in 18(26%) of the respondents ( Table   2 ). Distributions of oral lesions are shown in Table 2 . Majority 426 of the total number of patients in this study had been diagnosed of HIV for over a year while the remainder 65 were diagnosed within one 
Discussion
Various studies have shown prevalence of HIV-related oral lesions reduced significantly with the use of cART. The reported percentage decrease varied from 10% in a USA study [11] , 50% in a Mexican study [16] and 84% in a previous study in Lagos, Nigeria [7] . Although it could not be fully ascertained when the oral pigmentation occurred during the course of cART administration, majority of the patients were certain the pigmentation was not present before cART therapy except in one patient who had oral hyperpigmentation prior to cART administration. It was also observed that majority of participants with hyperpigmentation were either on Lamivudine,
Tenofovir or nevirapine containing regimen, none of which is known to be associated with hyperpigmentation. The major ARV which has been associated with oral hyperpigmentation is regimen containing zidovudine. [23] Zidovudine has an established adverse drug reaction of hyperpigmentation of the skin and nails [24] . Though antiretroviral drugs could be responsible for some of the oral hyperpigmentation seen in some studies [25, 26] cell count between 200-500 cell/mm 3 ) prior to cART initiation. There was significant improvement in the CD4+ cell count after cART administration in 11 of the respondents with post cART oral lesions.
These patients gave no prior history of oral lesions related to HIV before initiation of HAART. This further supports our suspicion that the hyperpigmentation may not be a direct manifestation of the disease, but perhaps is a side effect of medications used.
Conclusion
The prevalence of oral lesions in people living with HIV on cART therapy in Lagos is low. Oral hyperpigmentation and oral ulcers are the most frequently observed lesions. As the presence of oral lesions in PLWHIV in this study had no association with their CD4+ cell count; this study therefore infers that oral lesions seen in HIV patients on cART may not be a direct manifestation of the disease. 
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